Congress Materials - Team Phenomenal Hope 2025
2025 Team Phenomenal Hope | Dec 5 |Boston, MA
This section includes selected Johnson & Johnson Innovative Medicine abstracts, posters, or oral presentations, which have been accepted for congress presentations in the last 2 years or less (as determined by any congress restrictions on length of time materials can be posted). Information about pipeline products or investigational uses of products does not imply FDA approval for these products or uses, nor does it establish the safety or efficacy of these products or uses. Johnson & Johnson does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling. The content contained in this section is subject to congress copyright permissions.
Patient perspectives on engagement and shared decision-making in pulmonary arterial hypertension: A modified Delphi study
Sese D, Reed L, Cho M, Adhia A, Benninger C, Massaad R, Stone M, Bridge D, Enstone A, Smith H, Melendres-Groves L
This document will be available on Dec 5th, 2025
Practical considerations for managing transitions from parenteral prostacyclin agents to oral IP receptor agonist
Elwing JM, Benninger C, Strachan P, Triyasakorn K, Choren M, Timms K, Reed L
This document will be available on Dec 5th, 2025
Qualitative interviews of physicians managing patients with methamphetamine-associated Pulmonary Arterial Hypertension: Understanding the unmet medical need from a provider lens
Kingrey JF, Kim NH, Bartolome S, Lee HG, Sandros M, Lopez DA, Adhia A, Gearhart N, Cho M, Melendres-Groves L
This document will be available on Dec 5th, 2025
Qualitative interviews of patients with methamphetamine-associated Pulmonary Arterial Hypertension: Understanding the unmet medical need from the patient lens
Melendres-Groves L, de Jesus Perez V, Vaidya A, Lee HG, Sandros M, Lopez DA, Adhia A, Gearhart N, Cho M, Kingrey JF
This document will be available on Dec 5th, 2025
Delphi study to elicit consensus on best practice for prior authorization in pulmonary arterial hypertension (ENCORE PHPN)
Zeiger T, Alvadzhyan V, Marcello K, Carollo B, Perry R, Stone MA, Nuttall LA, Sandros M, Dong J, Lopez D, Gomez Rendon G, Adhia A, Benninger C, Muralidhar A
This document will be available on Dec 5th, 2025
Transitioning prostacyclin pathway agents to oral selexipag in patients with pulmonary arterial hypertension: A systematic literature (ENCORE PHPN)
Elwing J, Benninger C, Doad G, Hill W, Krishnan M, Parikh K, Sargent T, Wu S, Bridge D, O'Donovan P, Oswald C, Val-Maranes L, Miller C
This document will be available on Dec 5th, 2025
Copies of these presentations are for personal use only and may not be reproduced without written permission from the presentation author.
